T2 Biosystems

T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Shares of T2 Biosystems (NASDAQ: TTOO ) stock are rising higher after the medical diagnostics company disclosed that the Nasdaq Hearings Panel had provided it with an extension to regain compliance. T2 will have until May 20 to maintain a closing market capitalization of at least $35 million for at least 10 consecutive trading days.

TTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq Compliance

LEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that the Nasdaq Hearings Panel has granted the Company's request for continued listing on the Nasdaq Stock Market, subject to the Company demonstrating compliance with Nasdaq's market value of listed securities (“Market Value”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) on or before May 20, 2024.

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

T2 Biosystems Inc. (TTOO), a prominent player in the field of medical diagnostics, recently announced its financial results for the fourth quarter of 2023, signaling a pivotal moment for the company.

T2 Biosystems (TTOO) share price stays stable post Q4 earnings

T2 Biosystems, Inc. (TTOO) Q4 2023 Earnings Call Transcript

Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results

LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the entrance into a definitive agreement to convert $15 million of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems equity upon stockholder approval.

T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity

LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of territory exclusive distribution agreements for new geographies in the Netherlands, Belgium, and Vietnam, as well as the re-entry into Switzerland. Under the terms of the agreements, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel into these countries through our distribution partners.

T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia

Shares of T2 Biosystems (NASDAQ: TTOO ) are jumping higher by more than 30%. This comes as the diagnostics company announced that it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for Acinetobacter baumannii (A.

T2 Biosystems Receives 510(K) Clearance for Its Bacteria Panel

Increases number of bacteria species detected with addition of Acinetobacter baumannii Increases number of bacteria species detected with addition of Acinetobacter baumannii

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

T2 BioSystems (NASDAQ: TTOO) stock price has moved from one of the most popular names in Wall Street into a forgotten one. The shares have gone nowhere since October and are now sitting near their lowest level on record.

T2 BioSystems stock: brace for TTOO volatility this week

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the fourth quarter and full year 2023 and business updates after market close on Thursday, February 15, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra Cohen Foundation (“Cohen Foundation”) have selected T2 Biosystems as a Phase 2 winner in the LymeX Diagnostics Prize, a prize competition to accelerate the development of Lyme disease diagnostics. As a Phase 2 winner, T2 Biosystems will receive $265,000.

U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize

LEXINGTON, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced participation in the NIH-funded Antibacterial Resistance Leadership Group (ARLG) pilot study for pneumonia patients. The Pneumonia Direct Pilot study is a prospective, observational, diagnostic, feasibility study to determine the accuracy of multiple pathogen- and host-directed tests for the diagnosis of ventilator-associated pneumonia (VAP). Under the direction of Kimberly Hanson, M.D., University of Utah, the study seeks to explore new approaches for diagnosing VAP along with more comprehensive detection of antibiotic-resistant infections. The feasibility design is intended to inform future interventional studies that will investigate the clinical impact of combined pathogen and host-directed testing approaches.

T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) to expand the use of its FDA-cleared T2Candida® Panel to include pediatric testing.

T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric Testing

T2 BioSystems (NASDAQ: TTOO) stock price rose by more than 23% on Tuesday amid a short-squeeze and as some investors bought the dip. The shares jumped to a high of $4.81, its highest point sice mid-November.

What's going on with T2 Biosystems (TTOO) stock?

T2 Biosystems (NASDAQ: TTOO) stock price has collapsed to a record low as concerns about the company's future continued. Shares of the popular penny stock have collapsed to a split-adjusted low of $4.72, meaning they have plunged by over 92% this year.

T2 Biosystems (TTOO) stock price volatility has died: buy the dip?

Carvana

GameStop

Canoo

Moatable Inc

Soluna Holdings, Inc.

Tupperware

As 2024 approaches, it's time for investors to optimize their portfolios and identify which stocks to sell. It's far from being the most thrilling part of investing, but it's imperative.

Get Out Now! 7 Stocks That Are Destined to Die

LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NY.

T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

T2 Biosystems (NASDAQ: TTOO ) stock is in the green after the medical diagnostics company announced that it had received written notice from the Nasdaq Listing Qualifications Staff on Oct. 31 that it had regained compliance with Nasdaq's minimum bid requirement of $1. T2 had previously enacted a 1-for-100 reverse stock split that became effective as of Oct. 12 in order to lift TTOO stock above $1.

TTOO Stock Alert: T2 Biosystems Regains Nasdaq Compliance

LEXINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that on October 31, 2023 it received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company regained compliance with the minimum bid price requirement (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

T2 Biosystems Regains Compliance with Nasdaq Listing Requirements

Data demonstrates speed, accuracy, and clinical benefits of the T2Dx Instrument and T2 Biosystems' sepsis panels, including encouraging early detection data for T2Resistance Panel Data demonstrates speed, accuracy, and clinical benefits of the T2Dx Instrument and T2 Biosystems' sepsis panels, including encouraging early detection data for T2Resistance Panel

T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference

LEXINGTON, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”).

T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement

T2 Biosystems (NASDAQ: TTOO ) stock is plummeting lower following the company's announcement of a 1-for-100 reverse stock split and its preliminary third-quarter earnings. The reverse split was effective as of yesterday, with shares of TTOO beginning trading on a reverse split-adjusted basis as of this morning.

Why Is T2 Biosystems (TTOO) Stock Down 48% Today?

T2 Biosystems makes medical diagnostic testing equipment. The company reported a likely 60% in revenue in a preliminary third-quarter earnings report.

Why Shares of T2 Biosystems Are Falling Friday

T2 Biosystems, Inc. (NASDAQ:TTOO ) Preliminary Q3 2023 Earnings Call Transcript October 12, 2023 4:30 PM ET Company Participants Trip Taylor - IR John Sperzel - Chairman & CEO Conference Call Participants Kyle Mikson - Canaccord Ben Haynor - Alliance Global Partners Operator Greetings. Welcome to T2 Biosystems Preliminary Third Quarter 2023 Financial Results and Business Update Call.

News for T2 Biosystems Stock (TTOO)